Meningioma: A Pathology Perspective. Issue 1 (15th February 2021)

• Record Type: Journal Article
• Authors: Toland, Angus; Huntoon, Kristin; Dahiya, Sonika M
• Is Part Of: Neurosurgery. Volume 89:Issue 1(2021)
• Page Start: 11
• Page End: 21
• Publication Date: 2021-02-15
• Subjects: Meningioma -- WHO grade -- Histologic variants -- Immunohistochemistry -- Molecular -- Cytogenetics; Nervous system -- Surgery -- Periodicals; 617.48005
• DOI: 10.1093/neuros/nyab001
• Languages: English
• ISSNs: 0148-396X

Abstract

Abstract: Meningiomas are dural-based neoplasms that account for ∼37% of all intracranial tumors in the adult population. They can occur anywhere within the central nervous system and have a predilection for females. The World Health Organization classifies meningiomas into 3 grades based on increased risk of recurrence and associated mortality in grade III tumors. Although most tumors are categorized as low-grade, up to ∼15%-20% demonstrate more aggressive behavior. With the long-recognized association with neurofibromatosis type 2 gene mutation, putative driver mutations can be attributed to ∼80% of tumors. Several germline mutations have also been identified in some cases of familial meningiomatosis such as SMARCE1, SUFU, PTEN, and BAP1 . Finally, in addition to genetic data, epigenetic alterations, specifically deoxyribonucleic acid methylation, are being increasingly recognized for their prognostic value, potentially adding objectivity to a currently subjective grading scheme.